Within the partnership, Körber will provide comprehensive support to Taibang in various areas, including the implementation of software products, inspection and packaging machines, training, technology, project consulting, and the assistance for development of production information platforms. The collaboration encompasses in-depth cooperation across project planning and execution, production, and maintenance, as well as sharing of relevant solutions and experiences.
Taibang is currently implementing the newest version of Werum PAS-X MES, Körber’s market-leading manufacturing execution system for pharma, biotech and cell & gene therapy production, at its manufacturing base. The MES is expected to facilitate digital transformation and upgrades in areas such as processes, product quality control, and production efficiency, thereby fostering high-quality development in the blood products industry. PAS-X MES will be deployed as a full-scale MES at two Taibang sites – one in Tai’an and the other in Guiyang – covering complex processes from plasma melting to the finished product.
“As a national high-tech enterprise and one of the largest blood product groups in China, Taibang attaches great importance to R&D and production capacity,” says Hao Zhang, IT Director of Taibang, “Since Körber is an expert in technological innovation in the pharmaceutical industry worldwide, we believe that this cooperation will further enhance our overall strengths. Aligning with international cutting-edge digital solutions will enable us to increase production efficiency and quality, providing patients with safer blood products.”
Jerry Zheng, Managing Director of Körber Business Area Pharma China, adds: “We are pleased to establish a long-term strategic partnership with Taibang, which is an important milestone in our China business. Over the years, Körber has been helping customers in the pharma industry to achieve digitalization and information management with its end-to-end integrated technology solutions, enabling them to move quickly to the 'Factory of Excellence'. We look forward to writing a new chapter in the blood products industry together with Taibang.”
The Chinese National Medical Products Administration (NMPA) recently unveiled a set of regulations for blood products, including the “Three-Year (2024-2026) Action Plan for Smart Supervision of Blood Products Production”. These regulations aim to expedite the digitalization process, establish standards for the visualization of blood product manufacturing and inspection, and stimulate the transformation of blood product manufacturing. Ultimately, these measures are designed to ensure the safety, efficacy, and quality control of blood products.
Körber's software solutions, such as Werum PAS-X MES, are of great importance here. The strategic partnership will accelerate Taibang’s pace of product research and development with a commitment to enhancing product quality and production efficiency.
